Divieti P, John M R, Jüppner H, Bringhurst F R
Endocrine Unit, Wellman 5, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Endocrinology. 2002 Jan;143(1):171-6. doi: 10.1210/endo.143.1.8575.
The linear sequence of intact mammalian PTH consists of 84 amino acids, of which only the most amino(N)-terminal portion, i.e. PTH-(1-34), is required for the classical actions of the hormone on mineral ion homeostasis mediated by the type 1 PTH/PTHrP receptor (PTH1R). Like the N-terminus, the carboxyl (C)-terminal sequence of PTH is highly conserved among species, and various circulating PTH C-fragments are generated by peripheral metabolism of intact PTH or are directly secreted, in a calcium-dependent manner, by the parathyroid glands. Certain synthetic PTH C-fragments exert actions on bone and cartilage cells that are not shared by PTH-(1-34), and specific binding of PTH C-peptides has been demonstrated in bone cells in which PTH1R expression was eliminated by gene targeting. The peptide human (h) PTH-(7-84) recently was shown to inhibit the calcemic actions of hPTH-(1-34) or hPTH-(1-84) in parathyroidectomized animals. To determine whether this anticalcemic effect of hPTH-(7-84) in vivo might result from direct actions on bone, we studied its effects on both resorption of intact bone in vitro and formation of osteoclasts in primary cultures of murine bone marrow. Human (h) PTH-(7-84) (300 nM) reduced basal 72-h release of preincorporated (45)Ca from neonatal mouse calvariae by 50% (9.6 +/- 1.9% vs. 17.8 +/- 5.7%; P < 0.001) and similarly inhibited resorption induced by hPTH-(1-84), hPTH-(1-34), 1,25-dihydroxyvitamin D(3) (VitD), PGE(2), or IL-11. In 12-d murine marrow cultures, both hPTH-(7-84) (300 nM) and hPTH-(39-84) (3000 nM) lowered VitD-dependent formation of osteoclast-like cells by 70%. On the contrary, these actions of hPTH-(7-84) were not observed with the PTH1R antagonists hPTH-(3-34)NH(2) and [L(11),D-W(12),W(23),Y(36)]hPTHrP-(7-36)NH(2), which, unlike hPTH-(7-84), did inhibit PTH1R-dependent cAMP accumulation in ROS 17/2.8 cells. We conclude that hPTH-(7-84), acting via receptors distinct from the PTH1R and presumably specific for PTH C-fragments, exerts a direct antiresorptive effect on bone that may be partly due to impaired osteoclast differentiation.
完整的哺乳动物甲状旁腺激素(PTH)的线性序列由84个氨基酸组成,其中只有最氨基(N)端部分,即PTH-(1-34),是该激素对由1型PTH/PTHrP受体(PTH1R)介导的矿物质离子稳态的经典作用所必需的。与N端一样,PTH的羧基(C)端序列在物种间高度保守,各种循环的PTH C片段是由完整PTH的外周代谢产生的,或者由甲状旁腺以钙依赖的方式直接分泌。某些合成的PTH C片段对骨和软骨细胞有作用,而PTH-(1-34)则没有这些作用,并且已经在通过基因靶向消除了PTH1R表达的骨细胞中证明了PTH C肽的特异性结合。最近发现肽人(h)PTH-(7-84)可抑制甲状旁腺切除动物中hPTH-(1-34)或hPTH-(1-84)的升钙作用。为了确定hPTH-(7-84)在体内的这种抗升钙作用是否可能源于对骨的直接作用,我们研究了它对体外完整骨吸收和小鼠骨髓原代培养中破骨细胞形成的影响。人(h)PTH-(7-84)(300 nM)使新生小鼠颅骨中预先掺入的(45)Ca的基础72小时释放减少了50%(9.6±1.9%对17.8±5.7%;P<0.001),并同样抑制了由hPTH-(1-84)、hPTH-(1-34)、1,25-二羟基维生素D(3)(VitD)、前列腺素E2(PGE2)或白细胞介素-11诱导的吸收。在12天的小鼠骨髓培养中,hPTH-(7-84)(300 nM)和hPTH-(39-84)(3000 nM)都使VitD依赖的破骨细胞样细胞形成降低了70%。相反,PTH1R拮抗剂hPTH-(3-34)NH2和[L(11),D-W(12),W(23),Y(36)]hPTHrP-(7-36)NH2没有观察到hPTH-(7-84)的这些作用,与hPTH-(7-84)不同,它们确实抑制了ROS 17/2.8细胞中PTH1R依赖的环磷酸腺苷(cAMP)积累。我们得出结论,hPTH-(7-84)通过不同于PTH1R且可能对PTH C片段具有特异性的受体发挥作用,对骨产生直接的抗吸收作用,这可能部分归因于破骨细胞分化受损。